FAKTOR OPTIONSSCHEIN - MORPHOSYS Stock

Certificat

DE000PN2M0R3

Market Closed - Deutsche Boerse AG 03:20:22 2024-05-22 pm EDT
47.37 EUR -0.71% Intraday chart for FAKTOR OPTIONSSCHEIN - MORPHOSYS
Current month+6.43%
1 month-0.36%
Date Price Change
24-05-22 47.37 -0.71%
24-05-21 47.71 +0.44%
24-05-20 47.5 -4.92%
24-05-17 49.96 +0.56%
24-05-16 49.68 +5.17%

Delayed Quote Deutsche Boerse AG

Last update May 22, 2024 at 03:20 pm EDT

More quotes

Static data

Product typeExotic Products
Buy / SellCALL
Underlying MORPHOSYS AG
IssuerLogo Issuer BNP Paribas BNP Paribas
WKN PN2M0R
ISINDE000PN2M0R3
Date issued 2021-12-08
Strike 68.45
Maturity Unlimited
Parity 1 : 1
Emission price 50
Emission volume N/A
Settlement cash
Currency EUR

Technical Indicators

Highest since issue 52.24
Lowest since issue 3.18

Company Profile

MorphoSys AG is a global commercial-stage biopharmaceutical company based in Germany. The Company discovers, develops, and delivers cancer medicines to patients. It markets its proprietary medicine Monjuvi (tafasitamab-cxix) in the United States, a cancer immunotherapy treatment, used to treat patients in combination with lenalidomide with second and later lines of diffuse large B-cell lymphoma (DLBCL) who are not eligible for autologous stem cell transplant. Tafasitamab is also being evaluated in a global clinical trial as a first line therapy for DLBCL. Two additional product candidates are in late and mid-stage clinical development in oncology indications: pelabresib, a small-molecule BET inhibitor, is studied as a treatment for myelofibrosis, a type of bone marrow cancer for which treatment options are limited; and CPI-0209, a second generation EZH2 inhibitor, is studied for treating hematological and solid tumors.
Sector
-
More about the company

Ratings for MorphoSys AG

Trading Rating
Investor Rating
ESG Refinitiv
B-
More Ratings

Consensus: MorphoSys AG

Sell
Consensus
Buy
Mean consensus
HOLD
Number of Analysts
8
Last Close Price
68.2 EUR
Average target price
58.71 EUR
Spread / Average Target
-13.91%
Consensus